About Evox Therapeutics
Evox Therapeutics is a Healthcare company based in Oxford (United Kingdom) founded in 2016 by Samir El Andaloussi, Matthew Wood, and Per Lundin. Exosome-based gene therapies for neurological diseases are developed. Evox Therapeutics has raised $155.79 million across 6 funding rounds from investors including Gov.uk, TD Securities and Gates Foundation. The company has 58 employees. Its chief executive, as recorded, is Per Lundin. Evox Therapeutics offers products and services including ExoEdit Technology and Therapeutics Pipeline. Its focus areas include Life Sciences, Rare Diseases, Drugs and CNS. Its legal entity is EVOX THERAPEUTICS LIMITED.
Company details
Evox Therapeutics was founded in 2016 in Oxford, United Kingdom, within the biotechnology sector. Exosome-based therapies are developed to address neurological diseases through a proprietary CRISPRCas gene editing system encapsulated in exosomes. Genes such as ATXN2, linked to Spinocerebellar Ataxia type 2 and Amyotrophic Lateral Sclerosis, and MSH3, associated with Huntingtons disease and triplet repeat disorders, are targeted in the pipeline. Operations focus on gene modification for neurodegenerative conditions.
- Headquarters Oxford, United Kingdom
- Employees 58
- Founders Samir El Andaloussi, Matthew Wood, Per Lundin
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website evoxtherapeutics.com
- Social LinkedIn X
- Legal Name Evox Therapeutics Limited
- Date of Incorporation 22 Mar, 2016
- Jurisdiction OXFORD, OXFORDSHIRE, UNITED KINGDOM
- Annual Revenue$11.46 M (USD)29as on Dec 31, 2023
- Net Profit-$15.11 M (USD)11as on Dec 31, 2024
- EBITDA-$18.81 M (USD)14as on Dec 31, 2024
- Total Equity Funding$155.79M (USD)
in 6 rounds
- Latest Funding Round$95.97M (USD), Series C
Feb 2021
- InvestorsGov.uk
& 11 more
- Employee Count58
Products & Services of Evox Therapeutics
Evox Therapeutics offers a comprehensive portfolio of products and services, including ExoEdit Technology and Therapeutics Pipeline.
Delivers CRISPR-based gene editing via exosomes for disease treatment
Advances therapies for neurological diseases through exosome nanoparticles
Funding Insights of Evox Therapeutics
Evox Therapeutics has successfully raised a total of $155.79M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $95.97 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $155.79M
- Total Rounds 6
- Last Round Series C — $95.97M
- First Round $14.43M
(Apr 2016)
- Investors Count 12
All 6 funding rounds of Evox Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2021 | $95.97M | Series C | – | Redmile Group | |
| Mar 2019 | $1.97M | Grant | – | – | |
| Dec 2018 | Series B | – | Gates Foundation | – | |
| Nov 2018 | $843,645 | Grant | – | – | |
| Aug 2018 | $45.4M | Series B | – | Redmile Group | |
| Apr 2016 | $14.43M | Series A | – | Oxford Science Enterprises | – |
12 investors in total: 12 institutional.
Investors in Evox Therapeutics
Evox Therapeutics has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Gov.uk, TD Securities and Gates Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Long-term private equity investments in transformational opportunities are pursued. | invus.com | New York, United States | ||
Investment management services for science ventures are provided in Oxford. | oxfordscienceenterprises.com | Oxford, United Kingdom | ||
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Venture capital firm investing in seed & series A startups | borealis.vc | Hanover, United States | ||
A life sciences venture fund is operated with global reach. | panaceaventure.com | |||
Startups are incubated by Oxford University Innovation. | 1987 | innovation.ox.ac.uk | Oxford, United Kingdom | |
Operates as an employee-owned hedge fund focused on long/short equity strategies. | 2007 | redmilegroup.com | San Francisco, United States | |
Corporate finance advisory, mergers, acquisitions, and investment services are provided. | 1918 | cowen.com | New York, United States | |
Online government services and information are provided to users. | 1707 | gov.uk | London, United Kingdom |
Investor details for Evox Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Evox Therapeutics
42 people are tracked at Evox Therapeutics (8 in leadership, 11 in board & advisors, 23 in team); the tracked headcount is 58.
| Name | Role | Group |
|---|---|---|
Samir El Andaloussi | Co-Founder | Leadership |
Matthew Wood | Co-Founder | Leadership |
Per Lundin | Co-Founder & CEO | Leadership |
Kerry Jaycock | VP, People & Culture | Leadership |
Dave Carter | Head Of Research | Leadership |
Bob Higton | VP Finance & Operations | Leadership |
Heena Sharma | Associate Director, Pharmacology | Leadership |
Emma Lucas | Senior Director Legal | Leadership |
Sarah Gordon Wild | Director | Board & advisors |
Robert Langer | Scientific Advisor | Board & advisors |
Xandra Breakefield | Scientific Advisor | Board & advisors |
Anastasia Khvorova | Scientific Advisor | Board & advisors |
Pieter Vader | Scientific Advisor | Board & advisors |
Amrit Nagpal | Director | Board & advisors |
Martin Andrews | Director | Board & advisors |
John McHutchison | Director | Board & advisors |
Vidu Shanmugarajah | Board Observer | Board & advisors |
Kevin Raidy | Board Observer | Board & advisors |
Evan Caplan | Non-Executive Director | Board & advisors |
Angharad Evans | Senior Upstream Development Scientist | Team |
22 more people are available in the full profile.
Complete people profiles for Evox Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Evox Therapeutics
3 dated milestones of Evox Therapeutics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Evox Therapeutics is founded.
- Funding First funding round of $14.4M.
- Funding Latest funding round, Series C, of $96.0M.
Web traffic of Evox Therapeutics
The website of Evox Therapeutics (evoxtherapeutics.com) receives about 9K visits a month and ranks #2,464,657 among all websites worldwide, #3,382 in Biotechnology and Pharmaceuticals.
- Monthly visits9K
▼ 13.7% vs previous month
- Unique visitors4.3K
per month
- Global rank#2,464,657
among all websites
- Category rank#3,382
Health · Biotechnology and Pharmaceuticals
- Bounce rate79%
- Pages per visit1.2
- Average visit6 sec
- DevicesDesktop 6% · Mobile 94%
Websites whose visitors overlap most with Evox Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| oxb.com | 100% | 21.1K | #1,726,571 | View details | |
| genomics.com | 70% | 16.4K | #1,604,398 | View details | |
| gilead.com | 53% | 576.5K | #103,109 | View details | |
| labiotech.eu | 53% | 200.5K | #249,174 | View details | |
| ivy.farm | 37% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 7 similar websites and full traffic analytics for Evox Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 7 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Evox Therapeutics
Complete news archive for Evox Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Evox Therapeutics
Evox Therapeutics was founded in 2016.
Evox Therapeutics is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Per Lundin is the CEO of Evox Therapeutics, as recorded in our data. They have also founded this company.
Evox Therapeutics is a funded company, having raised a total of $155.79M across 6 funding rounds to date. The company's 1st funding round was a Series A of $14.43M, raised on Apr 2016.
Evox Therapeutics has 58 employees.
Annual revenue of Evox Therapeutics is $11.46M as on Dec 31, 2023.
Evox Therapeutics was founded in 2016 in Oxford, United Kingdom, within the biotechnology sector. Exosome-based therapies are developed to address neurological diseases through a proprietary CRISPRCas gene editing system encapsulated in exosomes. Genes such as ATXN2, linked to Spinocerebellar Ataxia type 2 and Amyotrophic Lateral Sclerosis, and MSH3, associated with Huntingtons disease and triplet repeat disorders, are targeted in the pipeline. Operations focus on gene modification for neurodegenerative conditions.
Evox Therapeutics offers ExoEdit Technology and Therapeutics Pipeline.
Evox Therapeutics has 12 investors. Key investors include Gov.uk, TD Securities, Gates Foundation, Orbimed, and Oxford University Innovation.
Evox Therapeutics operates through Evox Therapeutics Limited.